KPV (10mg)
BPC 157 (10mg)
TB 500 (10mg)
GHK-Cu (50mg)
KLOW is a multi-peptide research blend designed around a simple idea: recovery is rarely a single-pathway problem. By combining GHK-Cu, BPC-157, TB-500, and KPV in a single formulation, KLOW is positioned as a broad-spectrum tool for investigators interested in tissue remodeling, inflammation signaling, and restoration of barrier and connective structures. While each peptide has its own body of preclinical and emerging clinical discussion, the purpose of KLOW is to explore how these mechanisms may complement one another—collagen support and antioxidant activity alongside repair signaling, cell migration, and inflammation modulation—while keeping in mind that rigorous human data on blends remains limited and conclusions should be drawn conservatively.
Structure
Molecular composition and structural details of Klow
Sequence: Lys-Pro-Val
Molecular Formula: C16H30N4O4
Molecular Weight: 342.43 g mol−1342.43 gmol−1
PubChem CID: 125672
CAS Number: 67727-97-3
KLOW Overview
A four-peptide research blend discussed in tissue remodeling and inflammation contexts
KLOW is a commercially available multi-peptide preparation labeled to combine four bioactive peptides:GHK-Cu, KPV, Thymosin β4 (often marketed as “TB-500”), and BPC-157. The scientific rationale typically presented for such blends is pathway coverage: each peptide has been studied (largely in preclinical or translational settings) in biological processes relevant to tissue repair and inflammatory signaling.
Importantly, much of the supporting evidence base pertains to the individual components, not to thespecific four-peptide combination as a single, unified intervention. Any claim of “synergy” for a combined formulation should therefore be understood as a hypothesis unless directly demonstrated in controlled studies of the blend itself.
Typical Labeled Composition
Commonly described component list and amounts for KLOW-style formulations
KLOW products are commonly labeled as a four-peptide blend with a total mass per vial reflecting a dominant GHK-Cu fraction plus smaller amounts of the remaining peptides. A frequently described label format is 50 mg GHK-Cu and 10 mg each of KPV, Thymosin β4 (“TB-500”), and BPC-157 (80 mg total). Actual composition and purity are supplier-dependent and should be verified via appropriate analytical documentation.
GHK-Cu
Copper-binding tripeptide studied in connective tissue and skin remodeling contexts
GHK-Cu (glycyl-L-histidyl-L-lysine–copper complex) is a naturally occurring human tripeptide that binds copper. In the scientific literature, GHK-Cu is frequently discussed in relation to extracellular matrix remodeling and skin/connective tissue repair signaling. Mechanistic and translational work often focuses on processes such as fibroblast-associated remodeling programs and tissue maintenance pathways, with a substantial portion of evidence originating from in vitro and translational models.
KPV
α-MSH–derived tripeptide motif studied for anti-inflammatory and immunomodulatory effects
KPV (lysine–proline–valine) is commonly described as a short peptide motif derived from α-melanocyte-stimulating hormone (α-MSH). In research contexts, KPV is discussed for its anti-inflammatory and immune-modulating properties, including reported effects on inflammatory signaling pathways in experimental models. Interpretations are indication- and model-dependent, and the strength of evidence varies across systems.
Thymosin β4 (often marketed as “TB-500”)
Peptide associated with actin dynamics, cell migration, and angiogenesis-related biology
Thymosin β4 (Tβ4) is a naturally occurring peptide best known for roles in actin dynamics and is widely discussed in relation to cell migration and wound repair biology. The strongest peer-reviewed mechanistic foundation is centered on Tβ4 itself; “TB-500” is frequently used in commercial contexts to refer to thymosin β4–related products.
BPC-157
Gastric pentadecapeptide with extensive preclinical literature in protection and repair models
BPC-157 is a 15–amino-acid peptide described as a stable gastric peptide with a broad preclinical research footprint. It is frequently studied in experimental contexts involving gastrointestinal mucosal protectionand soft-tissue repair (e.g., muscle, tendon/ligament, and injury models). Reviews in recent years have emphasized that, despite extensive experimental work, robust human clinical evidence and safety data remain limited.
Rationale for a Multi-Peptide Blend
Conceptual pathway coverage (not proof of synergy)
The rationale commonly used to justify a four-peptide blend is that each component is discussed in the literature within different, but overlapping, biological domains relevant to repair:
• Inflammation modulation: often attributed to α-MSH/KPV-related pathways and downstream signaling effects in experimental models.
• Remodeling programs: commonly associated with GHK-Cu in connective tissue/skin remodeling contexts.
• Cell migration and vascular response biology: frequently discussed for thymosin β4.
• Protective/repair effects in injury models: commonly discussed for BPC-157 in experimental systems.
This framework describes why the combination is proposed, but it does not establish additive or synergistic outcomes without direct studies on the combined formulation.
PRODUCT USAGE
THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.